Advertisement
UK markets open in 3 hours 48 minutes

  • NIKKEI 225

    38,090.87
    +129.07 (+0.34%)
     

  • HANG SENG

    16,469.17
    +217.33 (+1.34%)
     

  • CRUDE OIL

    82.81
    +0.12 (+0.15%)
     

  • GOLD FUTURES

    2,388.80
    +0.40 (+0.02%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,769.88
    -1,533.19 (-2.99%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

GSK seeks U.S. approval for shingles vaccine Shingrix

Reuters - UK Focus

LONDON, Oct (HKSE: 3366-OL.HK - news) 24 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market.

Shingrix is viewed by analysts as among the British drugmaker's most promising experimental products, since it has shown greater protection among older recipients than Merck (Jakarta: 28586808.JK - news) & Co's rival shot Zostavax.

GSK said it planned to file Shingrix for European and Canadian approval before the end of this year, with Japan following in 2017.

(Reporting by Ben Hirschler; Editing by Susan Fenton)